Veterinary Pharmacovigilance Market Report 2026

The veterinary pharmacovigilance market size has grown rapidly in recent years. It will grow from $0.91 billion in 2025 to $1.03 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to limited formal pharmacovigilance frameworks in veterinary medicine, increasing use of veterinary pharmaceuticals, growth of companion animal healthcare spending, rising cases of adverse drug reactions in animals, regulatory mandates for drug safety monitoring.

The veterinary pharmacovigilance market size is expected to see rapid growth in the next few years. It will grow to $1.67 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to strengthening global veterinary drug regulations, increasing development of biologics and anti infectives, rising outsourcing of pharmacovigilance activities, growing demand for real-time safety monitoring solutions, expanding livestock and companion animal populations. Major trends in the forecast period include increasing regulatory scrutiny on veterinary drug safety, growing adoption of outsourced pharmacovigilance services, rising focus on post-marketing surveillance of veterinary drugs, expansion of adverse event reporting systems, increasing awareness of drug safety among veterinarians.

The increasing demand for animal health and medicinal products is expected to drive the growth of the veterinary pharmacovigilance market in the coming years. Animal health and medicinal products include items intended to maintain and improve the health and well-being of animals, such as medicines, nutritional products, and grooming solutions. The rising demand for these products is fueled by growing pet ownership, advancements in veterinary medicine, and the need to enhance livestock productivity. In addition, heightened awareness of animal welfare and a rising incidence of animal diseases are further contributing to increased demand. Veterinary pharmacovigilance plays a critical role in pet care by ensuring the safety and effectiveness of veterinary medicines through continuous monitoring, evaluation of adverse reactions, and regulatory compliance. For example, in March 2024, according to the Republic of Estonia’s Agency of Medicines (Ravimiamet), a national regulatory authority, the veterinary medicinal products sector grew by 6.9% in 2023, reaching €18.6 million, up from €17.4 million in 2022. Therefore, the growing demand for animal health and medicinal products is driving the expansion of the veterinary pharmacovigilance market.

Major companies operating in the veterinary pharmacovigilance market are concentrating on strengthening regulatory frameworks through advancements in data analytics, including adverse event reporting systems (REAS) and safety report preparation, to ensure the continued safety and efficacy of veterinary drugs. Adverse event reporting and safety report preparation involve the systematic documentation and analysis of harmful or unexpected reactions to veterinary medicines to assess risks and maintain compliance with regulatory requirements. For instance, in August 2024, the Ministry of Agriculture and Rural Development, a Mexico-based government agency, launched a national veterinary pharmacovigilance system. This monitoring platform, developed by SENASICA, is designed to ensure the safety, quality, and effectiveness of veterinary drugs in Mexico. The system gathers data on adverse reactions from stakeholders such as pharmaceutical manufacturers, distributors, veterinary hospitals, and veterinarians to identify, evaluate, and mitigate potential risks. It also incorporates the veterinary pharmacovigilance guide (REAS) to document adverse reactions and monitor efficacy, residue limits, and environmental impacts.

In January 2024, Veterinary Pharmaceutical Solutions, a U.S.-based veterinary services company, acquired Diamond Animal Health, Inc. for an undisclosed amount. Through this acquisition, Veterinary Pharmaceutical Solutions aimed to broaden its product portfolio, strengthen its research and development capabilities, and improve operational efficiency within the animal health sector. Diamond Animal Health, Inc. is a U.S.-based contract manufacturing and research organization that provides regulatory affairs consulting services, including support for veterinary pharmacovigilance activities.

Major companies operating in the veterinary pharmacovigilance market are Accenture PLC, Zoetis Inc, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Covetrus Inc, IDEXX Laboratories, Inc., Ceva Santé Animale, Virbac SA, Merck Animal Health, Huvepharma EOOD, Norbrook Laboratories Ltd, ProPharma Group, ArisGlobal LLC, PQE Group, Chanelle Pharma Group Ltd, Clinvet International, Ennov SAS, Sarjen Systems Pvt. Ltd, PharSafer Associates Ltd, Medfiles Oy, Azierta Contract Science Support Consulting, Knoell Germany GmbH, Triveritas Ltd, Leon Research, Biologit, Indivirtus Group.

North America was the largest region in the veterinary pharmacovigilance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary pharmacovigilance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary pharmacovigilance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the veterinary pharmacovigilance market by increasing costs associated with imported software platforms, data management tools, and consulting services. These effects are most noticeable in outsourced pharmacovigilance services and software solutions used by veterinary companies and CROs, particularly in North America, Europe, and Asia-Pacific regions. Higher operational costs may slow adoption among smaller firms. However, tariffs are encouraging regional service providers, local software development, and increased investment in in-house pharmacovigilance capabilities.

The veterinary pharmacovigilance market research report is one of a series of new reports that provides veterinary pharmacovigilance market statistics, including veterinary pharmacovigilance industry global market size, regional shares, competitors with a veterinary pharmacovigilance market share, detailed veterinary pharmacovigilance market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary pharmacovigilance industry. This veterinary pharmacovigilance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary pharmacovigilance is the field focused on detecting, assessing, understanding, and preventing adverse effects or other drug-related issues in animals. It involves monitoring and evaluating the safety and efficacy of veterinary medicines after their approval. The aim is to ensure that the benefits of these medicines outweigh the risks, thus promoting animal health and welfare while also protecting human health and the environment.

The main types of veterinary pharmacovigilance are in-house and outsourced. In-house pharmacovigilance involves the monitoring and assessment of adverse drug reactions and safety-related data conducted by the pharmaceutical or veterinary company itself. This includes the use of software and services for products such as biologics and anti-infectives. The scope covers various animal types, including companion animals, livestock, and others. End users of these services include veterinary hospitals, veterinary companies, and academic and research institutes.

The veterinary pharmacovigilance market consists of revenues earned by entities by providing services such as monitoring adverse drug reactions, assessing medication safety, collecting and analyzing safety data, conducting risk management, and ensuring regulatory compliance for veterinary medicines. The market value includes the value of related goods sold by the service provider or included within the service offering. The veterinary pharmacovigilance market also includes sales of databases, reporting systems, safety assessment tools, and monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.